EA201490822A1 - Модифицированные полипептиды рецептора активина и их применение - Google Patents

Модифицированные полипептиды рецептора активина и их применение

Info

Publication number
EA201490822A1
EA201490822A1 EA201490822A EA201490822A EA201490822A1 EA 201490822 A1 EA201490822 A1 EA 201490822A1 EA 201490822 A EA201490822 A EA 201490822A EA 201490822 A EA201490822 A EA 201490822A EA 201490822 A1 EA201490822 A1 EA 201490822A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
receptor polypeptides
activin receptor
proteins
modified activin
Prior art date
Application number
EA201490822A
Other languages
English (en)
Russian (ru)
Inventor
Йонгхун Сан
Лей-тинг Тони Тэм
Эйчкью Хэн
Кейт Су-ньюнг Квак
Ксяолан Жоу
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201490822A1 publication Critical patent/EA201490822A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
EA201490822A 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение EA201490822A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90545907P 2007-03-06 2007-03-06
US6547408P 2008-02-11 2008-02-11

Publications (1)

Publication Number Publication Date
EA201490822A1 true EA201490822A1 (ru) 2014-11-28

Family

ID=39739001

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201490822A EA201490822A1 (ru) 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение
EA200970810A EA020510B1 (ru) 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200970810A EA020510B1 (ru) 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение

Country Status (29)

Country Link
US (5) US7947646B2 (enExample)
EP (2) EP2132314B1 (enExample)
JP (1) JP5496682B2 (enExample)
KR (5) KR101633727B1 (enExample)
CN (2) CN105924516A (enExample)
AR (1) AR065611A1 (enExample)
AU (1) AU2008223338C9 (enExample)
BR (1) BRPI0808332A2 (enExample)
CA (1) CA2679841C (enExample)
CL (2) CL2008000664A1 (enExample)
CR (2) CR11054A (enExample)
CY (1) CY1118857T1 (enExample)
DK (1) DK2132314T3 (enExample)
EA (2) EA201490822A1 (enExample)
ES (1) ES2613043T3 (enExample)
HR (1) HRP20170323T1 (enExample)
HU (1) HUE032260T2 (enExample)
IL (2) IL200605A (enExample)
LT (1) LT2132314T (enExample)
MX (3) MX348286B (enExample)
NZ (1) NZ579369A (enExample)
PE (3) PE20171325A1 (enExample)
PH (1) PH12013502308A1 (enExample)
PL (1) PL2132314T3 (enExample)
PT (1) PT2132314T (enExample)
RS (1) RS55726B1 (enExample)
SI (1) SI2132314T1 (enExample)
TW (3) TWI573802B (enExample)
WO (1) WO2008109167A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
CN101277976B (zh) 2005-10-06 2012-04-11 伊莱利利公司 抗肌抑制素抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
UA98308C2 (en) 2006-09-05 2012-05-10 Эли Лилли Энд Компани Anti-myostatin antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2468291B1 (en) 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
AU2016210719B2 (en) * 2008-11-26 2018-03-29 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
ME02652B (me) 2008-11-26 2017-06-20 Amgen Inc Stabilizovana varijanta aktivin iib receptora
AU2013216639B2 (en) * 2008-11-26 2016-05-05 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
NO2424895T3 (enExample) 2009-04-27 2018-02-03
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
CA2779472C (en) * 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
ES2658292T3 (es) * 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
CA2808382A1 (en) 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
WO2012064338A1 (en) 2010-11-12 2012-05-18 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
PL2726099T3 (pl) * 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
US8871209B2 (en) 2011-11-14 2014-10-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
JP6145112B2 (ja) 2011-12-19 2017-06-07 アムジエン・インコーポレーテツド 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
JP6124986B2 (ja) 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）
US9453080B2 (en) 2012-06-11 2016-09-27 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
CN105530949A (zh) * 2013-03-15 2016-04-27 安姆根有限公司 人类受试者中的肌抑素拮抗作用
JP2016518357A (ja) 2013-04-08 2016-06-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨格筋幹細胞を若返らせる方法および組成物
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015073396A1 (en) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
AU2015274293A1 (en) * 2014-06-13 2017-02-02 Amgen Inc. Formulated receptor polypeptides and related methods
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
JP2017538701A (ja) * 2014-12-08 2017-12-28 ノバルティス アーゲー サルコペニアの治療のためのミオスタチンまたはアクチビンアンタゴニスト
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
US9744985B2 (en) 2015-02-17 2017-08-29 Hyundai Motor Company Rack bar unit of vehicle steering device
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
JP6810702B2 (ja) 2015-04-06 2021-01-06 アクセルロン ファーマ インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
KR20170135967A (ko) 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
RS61881B1 (sr) 2015-04-22 2021-06-30 Biogen Ma Inc Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
KR102457751B1 (ko) 2016-03-10 2022-10-21 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
EP3522913A4 (en) 2016-10-05 2020-10-28 Acceleron Pharma Inc. ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP3538123A4 (en) 2016-11-10 2020-10-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN120399032A (zh) 2018-01-12 2025-08-01 科乐斯疗法公司 激活素受体iib型变体及其使用方法
US11248044B2 (en) 2018-03-01 2022-02-15 Regeneron Pharmaceuticals, Inc. Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor
EP3790572A4 (en) 2018-05-09 2022-03-16 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20250041385A1 (en) * 2021-12-10 2025-02-06 Biogen Ma Inc. Modified actrii proteins and methods of use thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899886A (en) * 1959-08-18 rodth
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5349966A (en) 1976-10-18 1978-05-06 Hitachi Ltd Manufacture of semiconductor integrated circuit
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
ATE146749T1 (de) * 1991-07-05 1997-01-15 Nestle Sa Stabile kaffeekassette und verfahren zu ihrer herstellung
ATE129616T1 (de) * 1991-07-05 1995-11-15 Nestle Sa Gerät zum extrahieren von kartuschen, brauchbar für jede espressomaschine.
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
ATE378407T1 (de) 1994-04-29 2007-11-15 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2288036T5 (es) 1998-11-13 2017-07-06 Immunex Corporation ADN de TSLP humano y polipéptidos
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
JP2000262405A (ja) * 1999-03-18 2000-09-26 Soc Prod Nestle Sa 飲料抽出用密封カートリッジ
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
TWI236360B (en) * 2000-06-30 2005-07-21 Nestle Sa Capsule cage
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
SI1190959T1 (en) * 2000-09-26 2004-06-30 Societe Des Produits Nestle S.A. Capsule for beverage preparation with extraction under pressure
EP1203554A1 (fr) * 2000-11-03 2002-05-08 Societe Des Produits Nestle S.A. Dispositif pour l'extraction d'une substance alimentaire contenue dans un élément de recharge
PT1208782E (pt) * 2000-11-28 2004-10-29 Nestle Sa Dispositivo de percolacao
US6786134B2 (en) * 2002-02-07 2004-09-07 The Coca-Cola Company Coffee and tea dispenser
US20050188854A1 (en) * 2002-02-07 2005-09-01 The Coca-Cola Co. Coffee and tea dispenser
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
FR2842092B1 (fr) * 2002-07-12 2004-12-24 Seb Sa Machine a cafe fonctionnant avec des doses
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP2272864A3 (en) 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
US7785587B2 (en) 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
US20060196364A1 (en) * 2003-07-22 2006-09-07 The Coca-Cola Company Coffee & Tea Pod
US8327754B2 (en) * 2003-07-22 2012-12-11 The Coca-Cola Company Coffee and tea pod
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
US7074445B2 (en) * 2003-10-30 2006-07-11 Frito-Lay North America, Inc. Method for adhering large seasoning bits to a food substrate
BRPI0406606A (pt) 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
GB2411106B (en) * 2004-02-17 2006-11-22 Kraft Foods R & D Inc Cartridge for the preparation of beverages
US7323169B2 (en) 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
GB2416480B (en) * 2004-07-27 2007-12-27 Kraft Foods R & D Inc A system for the preparation of beverages
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1640756A1 (en) * 2004-09-27 2006-03-29 Barco N.V. Methods and systems for illuminating
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
DK1933871T3 (da) 2005-09-07 2013-07-08 Amgen Fremont Inc Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
EP1775234B1 (en) * 2005-10-14 2008-07-30 Nestec S.A. Capsule for the preparation of a beverage
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20080014860A1 (en) * 2006-07-14 2008-01-17 Lynn Byron Heitman Method and apparatus for eliminating register boxes, improving penetration sealing, improving airflow and reducing the labor costs to install ceiling registers
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2468291B1 (en) 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TWI782836B (zh) * 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8318135B2 (en) 2007-03-19 2012-11-27 National Research Council Of Canada Antagonist of ligands and uses thereof
US8431175B2 (en) * 2007-06-05 2013-04-30 Nestec S.A. Method for preparing a beverage or food liquid and system using brewing centrifugal force
JP5082676B2 (ja) * 2007-08-23 2012-11-28 株式会社サタケ 光学式穀物選別機
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US20100008918A1 (en) 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
JP2011527208A (ja) * 2008-07-08 2011-10-27 ネステク ソシエテ アノニム カプセルを使用する分量管理栄養システム及び方法
US8151694B2 (en) * 2008-08-01 2012-04-10 Keurig, Incorporated Beverage forming apparatus with centrifugal pump
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010026053A1 (en) * 2008-09-02 2010-03-11 Nestec S.A. Controlled beverage production device using centrifugal forces
ME02652B (me) 2008-11-26 2017-06-20 Amgen Inc Stabilizovana varijanta aktivin iib receptora
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
NO2424895T3 (enExample) 2009-04-27 2018-02-03
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
US20120295814A1 (en) 2010-01-08 2012-11-22 The Brigham And Women's Hospital, Inc. CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
JP6145112B2 (ja) 2011-12-19 2017-06-07 アムジエン・インコーポレーテツド 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
EP2802308A1 (en) 2012-01-13 2014-11-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AU2008223338B2 (en) 2012-12-20
US9447165B2 (en) 2016-09-20
CN101679980B (zh) 2016-05-11
US7947646B2 (en) 2011-05-24
CR11054A (es) 2009-10-30
CN105924516A (zh) 2016-09-07
KR20090127146A (ko) 2009-12-09
US20090227497A1 (en) 2009-09-10
TWI573802B (zh) 2017-03-11
US9809638B2 (en) 2017-11-07
PE20130615A1 (es) 2013-07-01
AU2008223338C9 (en) 2013-07-04
RS55726B1 (sr) 2017-07-31
MX389715B (es) 2025-03-20
TW200846359A (en) 2008-12-01
BRPI0808332A2 (pt) 2014-07-08
US20110183897A1 (en) 2011-07-28
SI2132314T1 (sl) 2017-03-31
US20140194355A1 (en) 2014-07-10
AR065611A1 (es) 2009-06-17
EP2132314A2 (en) 2009-12-16
CA2679841C (en) 2022-03-08
LT2132314T (lt) 2017-03-27
CL2008000664A1 (es) 2008-06-13
KR20140056393A (ko) 2014-05-09
EA020510B1 (ru) 2014-11-28
CR20150094A (es) 2015-04-14
PL2132314T3 (pl) 2017-07-31
CY1118857T1 (el) 2018-01-10
IL248322A0 (en) 2016-11-30
CL2015003139A1 (es) 2016-07-15
AU2008223338A1 (en) 2008-09-12
TWI454479B (zh) 2014-10-01
JP2010519931A (ja) 2010-06-10
IL200605A0 (en) 2011-08-01
CN101679980B8 (zh) 2017-02-22
MX2009009495A (es) 2009-09-15
NZ579369A (en) 2012-02-24
PT2132314T (pt) 2017-03-02
JP5496682B2 (ja) 2014-05-21
KR20160075861A (ko) 2016-06-29
US20180072791A1 (en) 2018-03-15
EA200970810A1 (ru) 2010-06-30
TW201441254A (zh) 2014-11-01
TW201718635A (zh) 2017-06-01
US8716459B2 (en) 2014-05-06
WO2008109167A2 (en) 2008-09-12
US20160264644A1 (en) 2016-09-15
PH12013502308A1 (en) 2015-12-02
PE20171325A1 (es) 2017-09-11
KR101633728B1 (ko) 2016-06-28
WO2008109167A3 (en) 2009-06-18
IL200605A (en) 2016-10-31
HRP20170323T1 (hr) 2017-04-21
EP2132314B1 (en) 2016-11-30
CN101679980A (zh) 2010-03-24
US10407487B2 (en) 2019-09-10
MX348286B (es) 2017-06-02
ES2613043T3 (es) 2017-05-22
HUE032260T2 (en) 2017-09-28
KR20150024444A (ko) 2015-03-06
KR101633727B1 (ko) 2016-06-28
DK2132314T3 (en) 2017-02-27
EP3141605A1 (en) 2017-03-15
CA2679841A1 (en) 2008-09-12
KR20120065374A (ko) 2012-06-20
KR101428344B1 (ko) 2014-08-13
AU2008223338C1 (en) 2013-06-20
PE20081804A1 (es) 2009-02-21

Similar Documents

Publication Publication Date Title
EA201490822A1 (ru) Модифицированные полипептиды рецептора активина и их применение
EA201491231A1 (ru) Варианты полипептидов рецептора активина и их применение
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201070996A1 (ru) Способы применения сопряженного с g-белком рецептора для идентификации стимуляторов секреции пептида yy(pyy) и соединений, пригодных для лечения состояний, модулируемых pyy
WO2008025020A3 (en) Cd30 binding agents and uses thereof
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200970251A1 (ru) Антитела к миостатину
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
WO2006058869A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2008103966A3 (en) Compositions and methods using toll-like receptors and unc93b
TW200602055A (en) Spray dried pharmaceutical compositions
MY155313A (en) Variant activin receptor polypeptides and uses thereof